![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CDER Denies Petition to Stay Approval of Abuse-Deterrent Opioid
CDER Denies Petition to Stay Approval of Abuse-Deterrent Opioid
November 3, 2017
The FDA declined a request from Pharmaceutical Manufacturing Research Services (PMRS), a contract drug manufacturer, to stay the approval of RoxyBond, Inspirion’s immediate-release abuse-deterrent opioid.
PMRS submitted the petition in May soon after the FDA approved RoxyBond as the first immediate-release opioid analgesic with abuse-deterrent label claims, claiming the associated safety hazards would tarnish the reputation of all abuse-deterrent opioids, including a product developed by PMRS.
In a response to the petition, CDER Director Janet Woodcock said the company had failed to demonstrate that the launch of Roxybond would cause it irreparable injury.
Upcoming Events
-
21Oct